RARE DISEASERESEARCH ATLAS
Open navigation menu

ORPHA:2822

Autosomal recessive spastic paraplegia type 11

high confidenceDisorder

Also known as: Nakamura-Osame syndrome · SPG11 · Spastic paraplegia-intellectual disability-thin corpus callosum syndrome

Publications

1,389

93.3th percentile

Trials

0

Interventional, condition-specific

Researchers

1,508

Distinct authors in sample

Gene link

SPG11

Definitive

Readiness

2/6

Stages with a signal

Clinical definition (Orphanet)

A complex spastic paraplegia characterized by lower limbs weakness and spasticity, upper limbs weakness, dysarthria, hypomimia, sphincter disturbances, peripheral , learning difficulties, cognitive impairment and dementia. Magnetic resonance imaging shows thin corpus callosum, cerebral atrophy, and periventricular white matter changes.

How rare: 1-9 / 1 000 000 — roughly one to nine people per million. In a city the size of Kolkata, perhaps a few dozen.

Orphanet entry

Cross-references

Joined from Mondo / Orphanet. MeSH labels may enter searches; UMLS / OMIM / NCIT are stored for reference.

Additional Mondo synonyms (6)

HSP-TCC · SPG11 hereditary spastic paraplegia · autosomal recessive spastic paraplegia type 11 · hereditary spastic paraplegia caused by mutation in SPG11 · hereditary spastic paraplegia type 11 · spastic paraplegia-intellectual disability-thin corpus callosum syndrome

Research stages

Trial readiness signals

Where this condition sits on an open-data research pipeline — not how close a treatment is, and not medical advice. Empty stages often mean “not in these databases under this Mondo ID,” not “impossible.”

2/6 stages with a signal

No matched interventional trial; the gene is known and literature exists — preclinical or natural-history work may still be the practical next step.

  1. Gene identifiedPresent

    Definitive — SPG11

  2. LiteraturePresent

    1,389 matched papers (1,067 in last 10 years) Source

  3. Phenotype characterisedNot checked

    Not yet enriched from Monarch / HPO

  4. Animal modelNot checked

    Not yet enriched from Monarch / Alliance

  5. Orphan designationNot checked

    FDA/EMA orphan-drug designation not enriched yet

  6. Interventional trialNot found

    No matched interventional trial under our ClinicalTrials.gov rules

Biology

Genes and phenotypes

Gene–disease validity from GenCC, plus phenotypes and animal models joined from Monarch Initiative via Mondo ID — not a clinical diagnosis aid.

Do we know what causes it?

Yes — we know a specific gene responsible (SPG11).

GenCC classification: Definitive.

Phenotypes (Monarch / HPO)

Not enriched in this build — Monarch phenotype joins were not run for this record.

Animal models (Monarch / Alliance)

Not enriched in this build.

Literature

Is anyone studying this?

1,389

1,389 papers have been published on this condition. That is a real research literature — still far smaller than common diseases (breast cancer: over 700,000 papers). Median papers in the last 10 years for a rare disease in this dataset (publications denominator n=5449) is 41.

1,389 papers since the earliest indexed year in this search — median last-10-year count for a rare disease in this dataset is 41 (publications denominator n=5449).

1,067 in the last 10 years · high confidence · 93.3th percentile (publications denominator)

Phrase hits: 1,389 · MeSH hits: 0

Open Europe PMC search

Who's working on it?

1,508

Distinct author names in 200 sampled papers — named people below.

Who's working on it?

No interventional trial matched this name; these authors publish on it in the sampled literature — a practical starting point for contact.

  1. 01
    Santorelli FM11 papers · 2026

    Neurobiology and Molecular Medicine, IRCCS Stella Maris, Pisa, Italy.

    Papers in Europe PMC
  2. 02
    Regensburger M8 papers · 2026

    Department of Stem Cell Biology, Friedrich-Alexander University (FAU) Erlangen-Nürnberg, Erlangen, Germany.

    Papers in Europe PMC
  3. 03
    Stevanin G8 papers · 2025

    Incia, Bordeaux university, CNRS, UMR5287, Bordeaux, France. giovanni-b.stevanin@inserm.fr.

    Papers in Europe PMC
  4. 04
    Darios F7 papers · 2026

    Sorbonne Université, Paris Brain Institute (ICM Institut du Cerveau), INSERM U1127, CNRS UMR 7225, Assistance Publique-Hôpitaux de Paris (AP-HP), Paris, France

    Papers in Europe PMC
  5. 05
    Ebrahimi-Fakhari D7 papers · 2026

    Department of Neurology and F.M. Kirby Neurobiology Center, Boston Children's Hospital, Harvard Medical School, Boston, Massachusetts, USA.

    Papers in Europe PMC
  6. 06
    Winkler J7 papers · 2026

    Department of Molecular Neurology, FAU Erlangen-Nürnberg, Erlangen, Germany.

    Papers in Europe PMC
  7. 07
    Branchu J6 papers · 2025

    Sorbonne Université, Paris Brain Institute (ICM Institut du Cerveau), INSERM U1127, CNRS UMR 7225, Assistance Publique-Hôpitaux de Paris (AP-HP), Paris, France

    Papers in Europe PMC
  8. 08
    Winner B6 papers · 2026

    Department of Stem Cell Biology, Friedrich-Alexander University (FAU) Erlangen-Nürnberg, Erlangen, Germany.

    Papers in Europe PMC
  9. 09
    Blackstone C5 papers · 2025

    Department of Neurology, Massachusetts General Hospital, Boston, MA, USA.

    Papers in Europe PMC
  10. 10
    Fatehi F5 papers · 2026

    Neuromuscular Research Center, Tehran University of Medical Sciences, Tehran, Iran.

    Papers in Europe PMC

Clinical research

Is a treatment being tested?

0

interventional trials for this specific condition

No interventional trial testing a treatment matched this specific condition name. 1 observational study did — shown below because natural-history and cohort work can be an important step toward a trial.

Data as of 27 July 2026

No matched interventional trials. This is true for 73% of diseases in the trials denominator (5114 of 7003). Here are the researchers publishing on it.

high confidence · 36.5th percentile (trials denominator)

Recruiting interventional trials

From the matched ClinicalTrials.gov set

No interventional trial testing a treatment was found for this specific condition name on ClinicalTrials.gov.

See who's working on it — people publishing on this disease are often the practical next contact when no trial is listed.

Observational and natural-history studies

1 observational study matches this condition. These do not test a treatment and are not counted in the interventional-trial headline, but they are genuine research: natural-history work often defines the endpoints needed for a future rare-disease trial, and families may be able to enroll.

Recruiting or not-yet-recruiting

Open the complete matched search on ClinicalTrials.gov

Where to find support

We do not yet link condition-specific patient organisations. These umbrella groups support undiagnosed and ultra-rare families:

India — NPRD

Last verified 2026-07-26

This ORPHAcode is not on our curated NPRD list (direct or Mondo-parent match). That does not decide clinical eligibility; families in India should ask a notified Centre of Excellence about current coverage.

Hand-curated for this project. ORPHAcode mappings are best-effort and may be incomplete or imprecise for umbrella categories. Parent (Mondo) matches mean the policy lists a broader category — confirm eligibility with a Centre of Excellence. Financial entitlements summarised from public policy statements and may change. This is not official government guidance.

How we counted this

Europe PMC query (preferred label + any corrected label + Orphanet and Mondo exact synonyms, stoplisted; unioned with resolved MeSH labels when available). UMLS / OMIM / NCIT cross-references are stored on the overview but are not added to the query string.

"Autosomal recessive spastic paraplegia type 11" OR "Nakamura-Osame syndrome" OR "SPG11" OR "Spastic paraplegia-intellectual disability-thin corpus callosum syndrome" OR "HSP-TCC" OR "SPG11 hereditary spastic paraplegia" OR "hereditary spastic paraplegia caused by mutation in SPG11" OR "hereditary spastic paraplegia type 11"

Run this search on Europe PMC

ClinicalTrials.gov query (quoted phrases + MeSH via query.cond, plus recall-expansion terms when used):

"Autosomal recessive spastic paraplegia type 11" OR "Nakamura-Osame syndrome" OR "SPG11" OR "Spastic paraplegia-intellectual disability-thin corpus callosum syndrome" OR "HSP-TCC" OR "SPG11 hereditary spastic paraplegia" OR "hereditary spastic paraplegia caused by mutation in SPG11" OR "hereditary spastic paraplegia type 11"

Study-type breakdown: 0 interventional · 1 observational · 0 expanded access. Only interventional studies enter the trial headline.

Query health: ok — strategies attempted: phrase; with hits: phrase

Run this search on ClinicalTrials.gov

Confidence reasoning

  • Preferred label is multi-word and distinctive
  • No synonyms dropped by stoplist
  • No label/synonym collisions with other diseases in this corpus

Ingested 2026-07-26T21:20:08.397Z